EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

Vlado Perkovic, Katherine R Tuttle iD, Peter Rossing iD, Kenneth W Mahaffey, Johannes F E Mann, George Bakris iD, Florian M M Baeres, Thomas Idorn, Heidrun Bosch-Traberg, Nanna Leonora Lausvig, Richard Pratley, FLOW Trial Committees and Investigators

New England Journal of Medicine · 11.07.2024 · 391 (2) · 109-121

DOI: 10.1056/nejmoa2403347 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 11.07.2024. Verfasst von Vlado Perkovic und 11 weiteren Autor:innen. Beteiligte Einrichtung: From the University of New South Wales, Sydney (V.P.); the Division of Nephrology, University of Washington School of Medicine, Seattle, and Providen…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Renal Insufficiency, Chronic, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 2049-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Novo Nordisk A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsRenal Insufficiency, ChronicGlucagon-Like Peptide-1 Receptor AgonistsAgedFemaleHumansMaleMiddle AgedCardiovascular DiseasesDiabetic NephropathiesDouble-Blind MethodGlomerular Filtration RateGlucagon-Like PeptidesInjections, SubcutaneousSemaglutide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsSemaglutide

Autor:innen und Institutionen

  • From the University of New South Wales, Sydney (V.P.); the Division of Nephrology, University of Washington School of Medicine, Seattle, and Providence Medical Research Center, Providence Inland Northwest Health, Spokan…

ORCID-Profile: Katherine R Tuttle, Peter Rossing, George Bakris

Förderung

  • Novo Nordisk A/S

Zitieren

APA

Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., Baeres, F. M. M., Idorn, T., Bosch-Traberg, H., Lausvig, N. L., Pratley, R., & FLOW Trial Committees and Investigators (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine, 391(2), 109-121. https://doi.org/10.1056/nejmoa2403347

Vancouver

Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 2024;391(2):109-121. doi:10.1056/nejmoa2403347

BibTeX
@article{Perkovic2024,
  author = {Perkovic, Vlado and Tuttle, Katherine R and Rossing, Peter and Mahaffey, Kenneth W and Mann, Johannes F E and Bakris, George and Baeres, Florian M M and Idorn, Thomas and Bosch-Traberg, Heidrun and Lausvig, Nanna Leonora and Pratley, Richard and FLOW Trial Committees and Investigators, FLOW Trial Committees and Investigators},
  title = {Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {2},
  pages = {109--121},
  doi = {10.1056/nejmoa2403347}
}
Kostenlos starten →